 "Marksans Pharma gains 9% on heavy volumes")
Shares of Marksans Pharma surged 9% to Rs 56.65 on BSE in an otherwise subdued market on the back of heavy volumes. The stock is trading close to its 52-week high of Rs 58.30 touched on October 4, last year in intra-day trade.
Till 01:02 pm; a combined 23.65 million equity shares representing 5.78% of total equity of pharmaceuticals firm changed hands on BSE and NSE. An average sub two million shares were traded daily in past two weeks.
Marksans Pharma today said that the United States Food and Drug Administration (USFDA) inspected the company’s manufacturing facility located in Goa from 3rd to 7th April, 2017.
“At the end of the inspection, there were 4 (four) observations given under Form 483. The company has already started addressing the same and is confident of satisfying the FDA within the stipulated time,” Marksans Pharma said in a regulatory filing.
Further, USFDA has also granted final approval of the Abbreviated New Drug Application for Dutasteride Soft Gelatin Capsules 0.5 mg, which is therapeutically equivalent to the reference listed drug (RLD), Avodart Capsules 0.5 mg of GlaxoSmithKline.
Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Marksans will launch the product immediately, it added.
Till 01:02 pm; a combined 23.65 million equity shares representing 5.78% of total equity of pharmaceuticals firm changed hands on BSE and NSE. An average sub two million shares were traded daily in past two weeks.
Marksans Pharma today said that the United States Food and Drug Administration (USFDA) inspected the company’s manufacturing facility located in Goa from 3rd to 7th April, 2017.
“At the end of the inspection, there were 4 (four) observations given under Form 483. The company has already started addressing the same and is confident of satisfying the FDA within the stipulated time,” Marksans Pharma said in a regulatory filing.
Further, USFDA has also granted final approval of the Abbreviated New Drug Application for Dutasteride Soft Gelatin Capsules 0.5 mg, which is therapeutically equivalent to the reference listed drug (RLD), Avodart Capsules 0.5 mg of GlaxoSmithKline.
Dutasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Marksans will launch the product immediately, it added.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%